Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News
SYS-CON.TV
Cloud Expo & Virtualization 2009 East
PLATINUM SPONSORS:
IBM
Smarter Business Solutions Through Dynamic Infrastructure
IBM
Smarter Insights: How the CIO Becomes a Hero Again
Microsoft
Windows Azure
GOLD SPONSORS:
Appsense
Why VDI?
CA
Maximizing the Business Value of Virtualization in Enterprise and Cloud Computing Environments
ExactTarget
Messaging in the Cloud - Email, SMS and Voice
Freedom OSS
Stairway to the Cloud
Sun
Sun's Incubation Platform: Helping Startups Serve the Enterprise
POWER PANELS:
Cloud Computing & Enterprise IT: Cost & Operational Benefits
How and Why is a Flexible IT Infrastructure the Key To the Future?
Click For 2008 West
Event Webcasts
Oncology Robotics Live Patient Doses. Health Robotics: 343,815 Doses; Intelligent Hospital Systems/RIVA: 1 Dose

BOZEN, Sud-Tirol, Italy, January 21, 2013 /PRNewswire/ --

Health Robotics reported today that it conducted a retrospective review of records for all "live" patient doses at its global Oncology Robot customers as of December 4, 2012, right after Intelligent Hospital Systems announced that their RIVA medical device had produced that same day its "first-ever chemotherapy patient dose".

Gaspar DeViedma, Health Robotics' Executive Vice President and Board Member, stated: "As of December 4, 2012, and not including the old generation robots with patents licensed to Loccioni [APOTECAchemo], Health Robotics "live patients" experience with both its 1st generation and 2nd generation robots were 343,200 doses on the old CytoCare technology, and 615 doses on the new i.v.STATION platform, for a total of 343,815 doses compared to 1 total chemo dose for RIVA. This sets the record straight after RIVA's much ballyhooed announcement last month, especially if compared with Health Robotics' proven "live" support for 60 chemotherapy and monoclonal antibody therapy active ingredients[1]."

Health-System Pharmacists are still questioning why it took so long for RIVA to make its first-ever chemotherapy dose at Princess Margaret Cancer Centre [Toronto], especially given the fact that IHS' precursor (Technology 2000) announced the chemotherapy robot as far back as a 1989 ASHP Journal article[2]. Moreover, IHS issued many chemotherapy installation news[3] releases at University of California San Francisco (12/2006, and same hospital again in 12/2009), Fresenius Kabi (02/2009), Royal Victoria in Barrie, Canada (01/2010), and Baxter Australia (02/2010). What really happened to all these other RIVA chemotherapy installations that had been waiting for many years before Princess Margaret? Why St. Boniface Hospital in Winnipeg has yet to implement its own 1989 invention after all these years? Should hospitals really expect 5+ years RIVA installation cycles?

About Health Robotics:

Founded in 2006 and now reaching 80% total IV Robots market share in the world [including over 90% the Oncology Robots global market], Health Robotics is the undisputed leading supplier of life-critical intravenous medication robots, providing over 300 hospital installations in 5 continents with the only fully-integrated robotics-based technology, IV Workflow, and manual compounding software automation solution. Health Robotics' second generation solutions [i.v.STATION, i.v.SOFT, and i.v.STATION ONCO] have been found [through scientific and peer-reviewed studies[1],[2]] to greatly contribute to ease hospitals' growing pressures to improve patient safety[4], increase throughput, and contain costs[1]. Through the effective and efficient production of sterile, accurate, tamper-evident and ready-to-administer IVs, Health Robotics' medical devices and integrated workflow solutions help hospitals eliminate life-threatening drug[1] and diluent[1] exchange errors, improve drug potency[5], decrease other medical mistakes and sterility risks, work more efficiently[1], reduce waste and controlled substances' diversion, and diminish the gap between rising patient volume/acuity, and scarce nursing and pharmacy staff. For more information, please visit: http://www.health-robotics.com

--------------------------------------------------

1. Asparaginase. Azacitidine, Bendamustin, Bevacizumab, Bleomycin, Bortezomib, Busulfan, Carboplatin, Cetuximab, Cisplatin, Cladribine, Clofarabine, Cyclophosphamide, Cytarabine, Dacarbazine, Dactinomycin, Daunorubicin, Decitabine, Docetaxel, Doxorubicin, Epirubicin, Etoposide, Fludarabine, Fluorouracil, Gemcitabine, Gemtuzumab, Ibrituximab, Idarubicin, Ifosfamide, Infliximab, Irinotecan, Ixabepilone, Liposomal Doxorubicin, Melphalan, Mesna, Methotrexate, Mitomycin, Mitoxantrone, Mitumomab, Nelarabine, Nimustine, Ofatumumab, Oxaliplatin, Paclitaxel, Panitumumab, Pemetrexed, Raltitrexed, Rituximab, Streptozocin, Tabalumab, Thiotepa, Topotecan, Trabecitabine, Trastuzumab, Treosulfan, Vinblastine, Vincristine, Vindesine and Vinorelbine.

2. Am J Hosp Pharm 46(11): 2286--93 1989. St. Boniface Hospital, Winnipeg.

3. http://www.intelligenthospitals.com/news.html

4. Impact of Robotic Antineoplastic Preparation on Safety, Workflow, Costs. Seger, Churchill, Keohane, Belisle, Wong, Sylvester, Chesnick, Burdick, Wien, Cotugno, Bates, and Rothschild. Brigham & Women's Hospital, Massachusetts College of Pharmacy, and Harvard Medical School. Journal of Oncology Practice, Nov. 2012, Volume 8, number 6.

5. Validation of an automated method for compounding monoclonal antibody patient doses: case studies of Avastin®, Remicade®, and Herceptin®. Peters, Capelle, Arvinte, van de Garde. St. Antonius Hospital. mAbs January 2013, Volume 5, Issue 1.

 

For additional information, please contact:
Claudia Perez
perez@health-robotics.com
Phone +1-786-417-1251

SOURCE Health Robotics

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Cloud Developer Stories
The Internet of Things (IoT) is rapidly in the process of breaking from its heretofore relatively obscure enterprise applications (such as plant floor control and supply chain management) and going mainstream into the consumer space. More and more creative folks are interconnecti...
Advanced Persistent Threats (APTs) are increasing at an unprecedented rate. The threat landscape of today is drastically different than just a few years ago. Attacks are much more organized and sophisticated. They are harder to detect and even harder to anticipate. In the foresee...
In his session at DevOps Summit, Tapabrata Pal, Director of Enterprise Architecture at Capital One, will tell a story about how Capital One has embraced Agile and DevOps Security practices across the Enterprise – driven by Enterprise Architecture; bringing in Development, Operati...
Disruptive macro trends in technology are impacting and dramatically changing the "art of the possible" relative to supply chain management practices through the innovative use of IoT, cloud, machine learning and Big Data to enable connected ecosystems of engagement. Enterprise i...
Dale Kim is the Director of Industry Solutions at MapR. His background includes a variety of technical and management roles at information technology companies. While his experience includes work with relational databases, much of his career pertains to non-relational data in the...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021



SYS-CON Featured Whitepapers
ADS BY GOOGLE